ATLANTA, GA — November 24, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that its Chairman & CEO, David Dodd, will present at NobleCon21 – the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference taking place December 2-3, 2025, in Boca Raton, FL.
David Dodd, Chairman & CEO of GeoVax Labs, will present a corporate update on December 3, 2025, at 3:00 pm ET at the Florida Atlantic University Executive Education Complex in Boca Raton, FL.
Interested investors and guests of GeoVax are welcome to attend at a discounted rate and can register using the discount code GOVXNOBLECON.
A high-definition video webcast of the presentation will be available the following day at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek: www.channelchek.com, the investor portal created by Noble. The webcast will be archived on the NobleCon website and on Channelchek.com for 90 days following the event.
Senior GeoVax management will also host one-on-one meetings with registered attendees.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines.
In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
Source: GeoVax Labs, Inc.
